⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
PSTV News
PLUS THERAPEUTICS, Inc. Common Stock
Form 8-K
sec.gov
PSTV
Form 8-K
sec.gov
PSTV
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
globenewswire.com
PSTV
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
globenewswire.com
PSTV
Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout
globenewswire.com
PSTV
Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™
globenewswire.com
PSTV
Plus Therapeutics Provides Business Update on REYOBIQ™ Clinical Program and U.S. CNSide® Commercialization
globenewswire.com
PSTV
Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET
globenewswire.com
PSTV
Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases
globenewswire.com
PSTV
Plus Therapeutics Expands CNSide Assay Platform to State of California
globenewswire.com
PSTV